NRXP vs. BCTX, FBIO, SPRB, ACXP, APRE, APLM, DARE, IPA, VIRX, and MRKR
Should you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include BriaCell Therapeutics (BCTX), Fortress Biotech (FBIO), Spruce Biosciences (SPRB), Acurx Pharmaceuticals (ACXP), Aprea Therapeutics (APRE), Apollomics (APLM), Daré Bioscience (DARE), ImmunoPrecise Antibodies (IPA), Viracta Therapeutics (VIRX), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical preparations" industry.
BriaCell Therapeutics (NASDAQ:BCTX) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings.
BriaCell Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.
BriaCell Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 1,194.96%. Given NRx Pharmaceuticals' higher possible upside, analysts clearly believe BriaCell Therapeutics is more favorable than NRx Pharmaceuticals.
In the previous week, NRx Pharmaceuticals had 7 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 9 mentions for NRx Pharmaceuticals and 2 mentions for BriaCell Therapeutics. BriaCell Therapeutics' average media sentiment score of 0.24 beat NRx Pharmaceuticals' score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.
NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.
15.4% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 21.8% of BriaCell Therapeutics shares are held by insiders. Comparatively, 21.1% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
NRx Pharmaceuticals received 3 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users.
Summary
BriaCell Therapeutics beats NRx Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NRx Pharmaceuticals Competitors List
Related Companies and Tools
